{"id":"soliris","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Nasopharyngitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Back pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypertension","drugRate":"","severity":"common","organSystem":""},{"effect":"Upper respiratory infection","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Anemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Cough","drugRate":"","severity":"common","organSystem":""},{"effect":"Peripheral edema","drugRate":"","severity":"common","organSystem":""},{"effect":"Urinary tract infections","drugRate":"","severity":"common","organSystem":""},{"effect":"Pyrexia","drugRate":"","severity":"common","organSystem":""},{"effect":"Musculoskeletal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"","severity":"common","organSystem":""},{"effect":"Influenza","drugRate":"","severity":"common","organSystem":""},{"effect":"Arthralgia","drugRate":"","severity":"common","organSystem":""},{"effect":"Pharyngitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Contusion","drugRate":"","severity":"common","organSystem":""}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Meningococcal sepsis","drugRate":"","severity":"serious"},{"effect":"Meningococcal meningitis","drugRate":"","severity":"serious"},{"effect":"Viral infection","drugRate":"2%","severity":"serious"},{"effect":"Headache","drugRate":"2%","severity":"serious"},{"effect":"Anemia","drugRate":"2%","severity":"serious"},{"effect":"Pyrexia","drugRate":"2%","severity":"serious"},{"effect":"Infection","drugRate":"","severity":"serious"},{"effect":"Progression of PNH","drugRate":"","severity":"serious"},{"effect":"Thrombotic event","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["Eculizumab","eculizumab"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722","title":"SOLIRIS (ECULIZUMAB) INJECTION, SOLUTION, CONCENTRATE [ALEXION PHARMACEUTICALS INC.]"},"ecosystem":[],"mechanism":{"target":"Complement C5"},"_scrapedAt":"2026-03-27T23:31:51.684Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Atypical hemolytic uremic syndrome","diseaseId":"atypical-hemolytic-uremic-syndrome","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Congenital hemolytic uremic syndrome","diseaseId":"congenital-hemolytic-uremic-syndrome","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Neuromyelitis optica","diseaseId":"neuromyelitis-optica","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Paroxysmal nocturnal hemoglobinuria","diseaseId":"paroxysmal-nocturnal-hemoglobinuria","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Refractory generalized myasthenia gravis","diseaseId":"refractory-generalized-myasthenia-gravis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05744921","phase":"PHASE3","title":"A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-03-07","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":202},{"nctId":"NCT07010302","phase":"PHASE4","title":"Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-05","conditions":"NMOSD","enrollment":540},{"nctId":"NCT07410039","phase":"PHASE4","title":"Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-02-01","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":200},{"nctId":"NCT07381205","phase":"","title":"Assessing the Incidence of Transplant Associated Thrombotic Microangiopathy (TA-TMA) in Adult Patients Undergoing Allogeneic Stem Cell Transplant (SCT)","status":"NOT_YET_RECRUITING","sponsor":"Manuel Ricardo Espinoza-Gutarra","startDate":"2026-07-01","conditions":"Transplant Associated Microangiopathy TAM, Transplant Complication","enrollment":85},{"nctId":"NCT05982938","phase":"","title":"Danicopan Early Access Program","status":"AVAILABLE","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"","conditions":"Paroxysmal Nocturnal Hemoglobinuria, PNH, Extravascular Hemolysis","enrollment":""},{"nctId":"NCT05133531","phase":"PHASE3","title":"A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-08-01","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":190},{"nctId":"NCT07420296","phase":"PHASE4","title":"Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder","status":"RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2026-01-01","conditions":"Neuromyelitis Optica Spectrum Disorders (NMOSD)","enrollment":198},{"nctId":"NCT04202341","phase":"","title":"Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2019-12-02","conditions":"Generalized Myasthenia Gravis","enrollment":500},{"nctId":"NCT03157635","phase":"PHASE1, PHASE2","title":"Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2016-11-14","conditions":"Paroxysmal Hemoglobinuria, Nocturnal","enrollment":59},{"nctId":"NCT07413250","phase":"","title":"Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2026-01-14","conditions":"Paroxysmal Nocturnal Hemoglobinuria, PNH","enrollment":50},{"nctId":"NCT07413679","phase":"","title":"Long-term Safety of Danicopan: IPIG Registry-based Cohort Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-08-18","conditions":"Paroxysmal Nocturnal Hemoglobinuria, PNH","enrollment":50},{"nctId":"NCT04434092","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-10-08","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":210},{"nctId":"NCT05966467","phase":"","title":"Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-02-01","conditions":"Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD","enrollment":122},{"nctId":"NCT04432584","phase":"PHASE3","title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-09-30","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":190},{"nctId":"NCT01374360","phase":"","title":"Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2004-10-29","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":6061},{"nctId":"NCT06764160","phase":"PHASE3","title":"Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-01-06","conditions":"Generalized Myasthenia Gravis (gMG), Refractory gMG","enrollment":15},{"nctId":"NCT06449001","phase":"PHASE3","title":"Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-08-11","conditions":"Paroxysmal Nocturnal Hemoglobinuria, PNH, Extravascular Hemolysis","enrollment":6},{"nctId":"NCT06799546","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy","status":"COMPLETED","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2025-02-13","conditions":"PNH","enrollment":73},{"nctId":"NCT06724809","phase":"PHASE3","title":"Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-01-16","conditions":"NMOSD, Neuromyelitis Optica Spectrum Disorders","enrollment":21},{"nctId":"NCT06448715","phase":"","title":"Real-World Treatment Study of Soliris (Eculizumab)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-05-28","conditions":"Observational","enrollment":11},{"nctId":"NCT05876351","phase":"PHASE3","title":"Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2023-07-14","conditions":"Atypical Hemolytic Uremic","enrollment":25},{"nctId":"NCT06513338","phase":"PHASE2","title":"Complement C5 mAb in the Treatment of Anti-GBM Disease","status":"COMPLETED","sponsor":"Peking University First Hospital","startDate":"2024-03-01","conditions":"Autoimmune Diseases","enrollment":16},{"nctId":"NCT06931691","phase":"","title":"A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-06-10","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":80},{"nctId":"NCT02113891","phase":"PHASE1, PHASE2","title":"Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-02","conditions":"Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation","enrollment":""},{"nctId":"NCT05805202","phase":"NA","title":"Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy","status":"RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2023-05-03","conditions":"Atypical Hemolytic Uremic Syndrome","enrollment":112},{"nctId":"NCT07184840","phase":"PHASE2","title":"Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder","status":"RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2025-09-09","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":110},{"nctId":"NCT07182409","phase":"","title":"Efficacy and Safety of Monoclonal Antibody in Acute Phase of Neuromyelitis Optica Spectrum Disorder","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2025-10-01","conditions":"NMOSD","enrollment":40},{"nctId":"NCT07177859","phase":"PHASE3","title":"A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients","status":"NOT_YET_RECRUITING","sponsor":"Nanjing Chia-tai Tianqing Pharmaceutical","startDate":"2025-11","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":78},{"nctId":"NCT06593938","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy","status":"COMPLETED","sponsor":"Chengdu Suncadia Medicine Co., Ltd.","startDate":"2024-10-25","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":76},{"nctId":"NCT06673394","phase":"PHASE2","title":"Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder","status":"WITHDRAWN","sponsor":"Tianjin Medical University General Hospital","startDate":"2025-09-03","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":""},{"nctId":"NCT06885957","phase":"","title":"Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-07-01","conditions":"NMO Spectrum Disorder","enrollment":200},{"nctId":"NCT04752566","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2021-03-08","conditions":"Guillain-Barre Syndrome","enrollment":57},{"nctId":"NCT04888507","phase":"PHASE2","title":"Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-07-08","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":6},{"nctId":"NCT06411626","phase":"","title":"Home Reported Outcomes in PNH","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-06-11","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":128},{"nctId":"NCT04935177","phase":"PHASE3","title":"Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx","status":"COMPLETED","sponsor":"Hansa Biopharma AB","startDate":"2021-10-14","conditions":"Kidney Transplantation in Highly Sensitized Patients","enrollment":64},{"nctId":"NCT05274633","phase":"","title":"Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2022-06-17","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":120},{"nctId":"NCT06987864","phase":"PHASE3","title":"An Extension Clinical Study of BCD-148 for the Treatment of Patients With PNH Previously Treated in Clinical Study No. BCD-148-2/NOCTURN","status":"COMPLETED","sponsor":"Biocad","startDate":"2020-04-13","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":24},{"nctId":"NCT06932744","phase":"PHASE3","title":"Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy","status":"RECRUITING","sponsor":"Wuhan Createrna Science and Technology Co., Ltd","startDate":"2024-08-30","conditions":"Paroxysmal Nocturnal Haemoglobinuria (PNH)","enrollment":66},{"nctId":"NCT03427060","phase":"PHASE2","title":"Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms","status":"COMPLETED","sponsor":"AKARI Therapeutics","startDate":"2018-05-14","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":1},{"nctId":"NCT04469465","phase":"PHASE3","title":"Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-12-16","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":86},{"nctId":"NCT05886244","phase":"PHASE3","title":"Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2023-07-05","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":25},{"nctId":"NCT04702568","phase":"PHASE2","title":"A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"TERMINATED","sponsor":"BioCryst Pharmaceuticals","startDate":"2020-12-18","conditions":"Paroxysmal Nocturnal Hemoglobinuria, PNH","enrollment":19},{"nctId":"NCT05131204","phase":"PHASE3","title":"Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-10-06","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":3},{"nctId":"NCT05731050","phase":"PHASE2","title":"Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"NOT_YET_RECRUITING","sponsor":"NovelMed Therapeutics","startDate":"2026-06","conditions":"PNH - Paroxysmal Nocturnal Hemoglobinuria","enrollment":6},{"nctId":"NCT04859608","phase":"PHASE3","title":"Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU)","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2021-10-20","conditions":"Hemolytic-Uremic Syndrome, Atypical","enrollment":40},{"nctId":"NCT06888622","phase":"","title":"BLAZE-Limiting Approach in NMOSD","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2023-10-01","conditions":"Neuromyelitis Optica Spectrum Disorders (NMOSD)","enrollment":9},{"nctId":"NCT03056040","phase":"PHASE3","title":"ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2017-05-17","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":202},{"nctId":"NCT05646563","phase":"PHASE2","title":"Study of NM8074 in Adult PNH Patients with Inadequate Response to Soliris","status":"NOT_YET_RECRUITING","sponsor":"NovelMed Therapeutics","startDate":"2026-01","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":12},{"nctId":"NCT05116774","phase":"PHASE2","title":"BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy","status":"TERMINATED","sponsor":"BioCryst Pharmaceuticals","startDate":"2021-12-06","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":12},{"nctId":"NCT05337683","phase":"","title":"A Retrospective Non-Interventional Study to Evaluate the Impact of Eculizumab in Korean PNH Patients","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2020-12-11","conditions":"PNH","enrollment":80},{"nctId":"NCT05405777","phase":"","title":"A Retrospective Study to Evaluate the Clinical Outcome According to Treatment in aHUS Patients in South Korea","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2022-10-04","conditions":"aHUS","enrollment":97},{"nctId":"NCT03759366","phase":"PHASE3","title":"A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2018-12-28","conditions":"Myasthenia Gravis, Myasthenia Gravis, Juvenile Form, Myasthenia Gravis, Generalized","enrollment":12},{"nctId":"NCT04170023","phase":"PHASE2","title":"Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2019-12-16","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":29},{"nctId":"NCT04558918","phase":"PHASE3","title":"Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-01-25","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":97},{"nctId":"NCT04155424","phase":"PHASE2, PHASE3","title":"A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-01-14","conditions":"Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder","enrollment":5},{"nctId":"NCT03748823","phase":"PHASE3","title":"Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2019-02-19","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":139},{"nctId":"NCT04320602","phase":"PHASE4","title":"Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2021-04-14","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":18},{"nctId":"NCT02714374","phase":"PHASE1","title":"GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers","status":"TERMINATED","sponsor":"Andrew Lowy","startDate":"2016-03-25","conditions":"Solid Organ Cancers","enrollment":5},{"nctId":"NCT06453135","phase":"PHASE1, PHASE2","title":"Eculizumab for Prevention of Antibody-Mediated Rejection in ABO-Incompatible Living Donor Kidney Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Tao Lin","startDate":"2024-07","conditions":"Kidney Transplantation","enrollment":30},{"nctId":"NCT03439839","phase":"PHASE2","title":"Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-04-09","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis","enrollment":16},{"nctId":"NCT02946463","phase":"PHASE3","title":"ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2016-12-12","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":272},{"nctId":"NCT04351503","phase":"","title":"A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-04-09","conditions":"SARS Coronavirus (SARS-CoV-2) Infection","enrollment":126586},{"nctId":"NCT04058158","phase":"PHASE3","title":"A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2019-08-07","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":50},{"nctId":"NCT05726916","phase":"PHASE3","title":"Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-11-09","conditions":"Hypertensive Emergency-associated Hemolytic Uremic Syndrome","enrollment":66},{"nctId":"NCT03472885","phase":"PHASE2","title":"Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2018-05-08","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":12},{"nctId":"NCT04725812","phase":"PHASE2","title":"Complement Regulation to Undo Systemic Harm in Preeclampsia","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2021-09-13","conditions":"Preeclampsia, Severe Preeclampsia, Eculizumab","enrollment":2},{"nctId":"NCT05863442","phase":"PHASE1","title":"Comparative PK, Safety, Tolerability, Immunogenicity, and PD Profile Study of TUR03 and Soliris in Healthy Participants","status":"UNKNOWN","sponsor":"Turgut Ardika PTY LTD","startDate":"2023-04-10","conditions":"Healthy","enrollment":120},{"nctId":"NCT04103489","phase":"PHASE1","title":"The Use of Eculizumab in HELLP Syndrome","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2021-02-23","conditions":"HELLP Syndrome (HELLP), Third Trimester, Complement Abnormality, Morbidity;Newborn","enrollment":3},{"nctId":"NCT06098378","phase":"","title":"Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With Eculizumab","status":"UNKNOWN","sponsor":"University Hospital, Strasbourg, France","startDate":"2023-06-07","conditions":"Thrombotic Microangiopathies","enrollment":30},{"nctId":"NCT03518203","phase":"PHASE2","title":"Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-08-03","conditions":"Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome, Multiple Organ Dysfunction Syndrome","enrollment":23},{"nctId":"NCT04671810","phase":"","title":"Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria®","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2019-06-13","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":44},{"nctId":"NCT01770951","phase":"","title":"A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2009-08-31","conditions":"Atypical Hemolytic Uremic Syndrome (aHUS)","enrollment":30},{"nctId":"NCT02591862","phase":"PHASE2","title":"Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)","status":"COMPLETED","sponsor":"AKARI Therapeutics","startDate":"2016-02","conditions":"Paroxysmal Nocturnal Haemoglobinuria (PNH)","enrollment":1},{"nctId":"NCT03818607","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-01-22","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":42},{"nctId":"NCT05842486","phase":"","title":"Hematological Response in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Anti-C5 Antibody: an External Control Arm Study for Iptacopan Use in Anti-C5 naïve Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-01-18","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":92},{"nctId":"NCT03406507","phase":"PHASE3","title":"A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2018-02-22","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":13},{"nctId":"NCT05702996","phase":"PHASE3","title":"Multicenter, Uncontrolled Pilot Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies","status":"UNKNOWN","sponsor":"University Hospital, Rouen","startDate":"2023-03","conditions":"Thrombotic Microangiopathies","enrollment":10},{"nctId":"NCT04079257","phase":"","title":"The Pharmacokinetics and Pharmacodynamics of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2021-02-23","conditions":"Paroxysmal Nocturnal Hemoglobinuria, Eculizumab, PK-PD","enrollment":27},{"nctId":"NCT02003144","phase":"PHASE3","title":"An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2015-01-12","conditions":"Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder","enrollment":119},{"nctId":"NCT04749810","phase":"","title":"Observational Study of Elizaria® in aHUS Patients","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2019-12-19","conditions":"Atypical Hemolytic Uremic Syndrome, aHUS","enrollment":50},{"nctId":"NCT03078582","phase":"PHASE2","title":"Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients","status":"COMPLETED","sponsor":"Ra Pharmaceuticals","startDate":"2017-03-08","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":26},{"nctId":"NCT03030183","phase":"PHASE2","title":"Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab","status":"COMPLETED","sponsor":"Ra Pharmaceuticals","startDate":"2017-04-17","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":3},{"nctId":"NCT03500549","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"COMPLETED","sponsor":"Apellis Pharmaceuticals, Inc.","startDate":"2018-06-14","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":80},{"nctId":"NCT04802083","phase":"","title":"COVID-19 Soliris Expanded Access Protocol","status":"NO_LONGER_AVAILABLE","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"","conditions":"Covid19","enrollment":""},{"nctId":"NCT04463056","phase":"PHASE3","title":"Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNH","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2017-11-29","conditions":"Paroxysmal Nocturnal Hemoglobinuria, Marchiafava-Micheli Syndrome, Paroxysmal Hemoglobinuria","enrollment":32},{"nctId":"NCT02013037","phase":"PHASE3","title":"The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2012-11","conditions":"Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction","enrollment":36},{"nctId":"NCT03468140","phase":"EARLY_PHASE1","title":"Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation","status":"WITHDRAWN","sponsor":"Yale University","startDate":"2021-10-01","conditions":"End Stage Liver Disease","enrollment":""},{"nctId":"NCT03999840","phase":"PHASE2","title":"Eculizumab to Cemdisiran Switch in aHUS","status":"WITHDRAWN","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-01","conditions":"Atypical Hemolytic Uremic Syndrome","enrollment":""},{"nctId":"NCT04355494","phase":"","title":"SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19","status":"NO_LONGER_AVAILABLE","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"","conditions":"COVID-19, Pneumonia, Viral, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)","enrollment":""},{"nctId":"NCT04060264","phase":"PHASE3","title":"Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria","status":"COMPLETED","sponsor":"Biocad","startDate":"2019-04-04","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":28},{"nctId":"NCT04679103","phase":"PHASE3","title":"A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC \"GENERIUM\", Russian Federation)","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2018-05-03","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":50},{"nctId":"NCT01029587","phase":"PHASE2","title":"Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-11","conditions":"Antiphospholipid Antibody Syndrome, End Stage Renal Disease","enrollment":1},{"nctId":"NCT03574506","phase":"","title":"Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associated aHUS: A Case Series","status":"UNKNOWN","sponsor":"Fundación Grupo de Investigación en Cuidados Intensivos y Obstetricia","startDate":"2018-04-15","conditions":"Atypical Hemolytic Uremic Syndrome, Pregnancy","enrollment":50},{"nctId":"NCT04027803","phase":"PHASE1","title":"Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®","status":"COMPLETED","sponsor":"Biocad","startDate":"2018-09-21","conditions":"Healthy Subjects","enrollment":78},{"nctId":"NCT04346797","phase":"PHASE2","title":"CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-16","conditions":"SARS-CoV-2, COVID19","enrollment":120},{"nctId":"NCT04288713","phase":"","title":"Eculizumab (Soliris) in Covid-19 Infected Patients","status":"AVAILABLE","sponsor":"Hudson Medical","startDate":"","conditions":"Coronavirus","enrollment":""},{"nctId":"NCT02301624","phase":"PHASE3","title":"Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2014-11-12","conditions":"Refractory Generalized Myasthenia Gravis","enrollment":117},{"nctId":"NCT03722329","phase":"PHASE1","title":"Pharmacokinetic, Safety, Tolerability, Immunogenicity, and Pharmacodynamic Study of SB12 in Healthy Subjects","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2018-11-13","conditions":"Healthy","enrollment":240},{"nctId":"NCT02614898","phase":"","title":"Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2015-11-04","conditions":"Atypical Hemolytic Uremic Syndrome","enrollment":67},{"nctId":"NCT02574403","phase":"PHASE4","title":"Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2015-11","conditions":"Atypical Hemolytic Uremic Syndrome","enrollment":58}],"_emaApprovals":[],"_faersSignals":[{"count":5939,"reaction":"FATIGUE"},{"count":4244,"reaction":"OFF LABEL USE"},{"count":4030,"reaction":"HAEMOGLOBIN DECREASED"},{"count":3536,"reaction":"HEADACHE"},{"count":2582,"reaction":"DEATH"},{"count":2429,"reaction":"PYREXIA"},{"count":2174,"reaction":"DYSPNOEA"},{"count":2020,"reaction":"ASTHENIA"},{"count":2007,"reaction":"NAUSEA"},{"count":1908,"reaction":"HAEMOLYSIS"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[{"date":"20121221","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20180725","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20170113","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20190627","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20141010","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20110923","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20151203","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20100604","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20250228","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20240208","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20250627","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20070316","type":"ORIG","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20180725","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20201120","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20180228","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20200407","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20171023","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20160413","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20151203","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20140430","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20140430","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20240919","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20240628","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20090630","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"},{"date":"20240322","type":"SUPPL","sponsor":"ALEXION PHARM","applicationNumber":"BLA125166"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"approved","brandName":"Soliris","genericName":"Soliris","companyName":"Apellis Pharmaceuticals, Inc.","companyId":"apellis-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":12,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}